Logo Cellply

Cellply to present new method for evaluating immunotherapy efficacy at the 61th ASH Annual Meeting

Events

Cellply to present new method for evaluating immunotherapy efficacy at the 61th ASH Annual Meeting

Bologna (Italy), 25 November 2019.

Cellply announced today that the company will present an abstract with new results about its novel Inter-Cell Networking Profiling (ICNP) technology at the 61th Annual Meeting and Exposition of the American Society of Hematology (ASH), on December 7-10 in Orlando, FL, USA.

“There is an unmet need in oncology to expand current precision medicine approaches to cancer immunotherapy” says Massimo Bocchi, CEO at Cellply. “The work we will present at the next ASH congress represents an important step forward in the combined evaluation of drug action and immune system activity. Our work, leveraging on our unique ability to generate thousands of microtumors in a single automated test and select the cell networks better mimicking the in-vivo cell behavior, provides an unprecedented method to screen antibody therapies with immune-mediated mechanisms of action. Starting from these results we are currently working with biopharmaceutical companies and research institutes to generate novel and effective immuno-oncology therapeutics”.

The abstract is the results of a scientific collaboration with hematologists and scientists from Prof. Cavo’s team working on Multiple Myeloma at Seragnoli Institute of Sant’Orsola Polyclinic in Bologna (Italy). The work is supported by the ONCOSMART project, funded by the European Commission under the SME Instrument (Phase 2) programme.

Title: Inter-Cell Networking Profiling Enables Comprehensive Characterization of Immune-Mediated Activity of Anti-CD38 Therapy through Ex-Vivo Analysis of Multiple Myeloma Patients
Authors: Alice Bettelli, Rita Ruggiano, Silvia Bocchi, Laura Rocchi, Andrea Faenza, Enrica Borsi, Carolina Terragna, Elena Zamagni, Marina Martello, Marco Bettelli, Laura Rambelli, Viviana Guadagnuolo, Nicola Pecorari, Luca Giulianelli, Matteo Pisani, Dario Biscarini, Michele Cavo, Roberto Guerrieri and Massimo Bocchi
Abstract ID: 3372
Date/Time: Sunday, December 8, 2019, 6:00 PM-8:00 PM
Location: Hall B, Level 2 (Orange County Convention Center)
Session: 803. Emerging Diagnostic Tools and Techniques: Poster II

Link to abstract

Download poster

continue reading

You may also like

Press release

Advancing TCR-based Cell Therapies & Bispecific Approaches

24 April 2024
Press release

Nature Biotechnology publishes research from DKFZ and Cellply highlighting novel approach for accelerating cellular immunotherapy development

19 March 2024
Events

Dual attendance for Cellply at March’s leading events in the cell therapy industry.

18 March 2024
Events

Launch of VivaCyte® at Advanced Therapies Week 2024

26 January 2024
News

Cellply launches its end-to-end single cell potency characterization platform VivaCyte

17 January 2024
Events

Cellply at Advanced Therapies Week 2024

4 January 2024
Press release

Cellply concludes a new internal round of €3.6 million and extends the round to new investors!

27 September 2023
News

CellPly announces acceptance of one abstract at the CICON23 conference

18 September 2023
Press release

CellPly announces Emiliano Spagnolo as the new CEO

27 July 2023
News

L’innovazione Cellply in un articolo sulla rivista Le Scienze

4 March 2020
News

Cellply wins the €300k Gaetano Marzotto prize and Unicredit StartLab prize

22 November 2018
Events

Cellply invited to present at the World Health Summit 2019

22 October 2018
Press release

Cellply secures €2.34m non-dilutive grant funding from the European Commission for a novel precision oncology diagnostic platform

24 May 2018
News

Cellply selected as finalist at Lyfebulb Oncology Award

1 March 2018
Events

Cellply abstract accepted at the AACR 2018 Annual Meeting

4 February 2018
Press release

Cellply and Sant’Orsola-Malpighi Polyclinic to present one abstract on AML patient stratification with the Open Microwell platform at the 58th ASH Annual Meeting

4 November 2016
News

Cellply wins an H2020 SME Instrument Phase 1 grant

20 October 2016
Keep in touch

Need some infos?

Drop us a line or give us a ring. We love to hear from you and are happy to answer any questions.